ChristopherDRiemannMD

Retinal Disease

Member, Board of Directors - Cincinnati Eye Institute Director, Vitreoretinal Fellowship - Cincinnati Eye Institute and University of Cincinnati Section Head Ophthalmology, Bethesda North Hospital

Join to view full profile

Dr. Riemann is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Riemann's full profile

Already have an account?

Office
1945 Cei Drive
Cincinnati, OH 45242
Phone+1 513-984-5133

Fax+1 513-569-3941

Education & Training

Cleveland Clinic FoundationResidency, Ophthalmology, 1995 - 1998
York HospitalInternship, Transitional Year, 1994 - 1995
University of Maryland School of MedicineClass of 1994

Certifications & Licensure

OH State Medical License 1995 - 2026
KY State Medical License 1999 - 2025
PA State Medical License 1994 - 1995
American Board of Ophthalmology Ophthalmology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification NextGen Ambulatory EHR, NextGen Healthcare, 2012-2013
Fellow (FAAO) American Academy of Ophthalmology

Clinical Trials

Treatment for Presumed Ocular Histoplasmosis Start of enrollment: 2013 Mar 01
Unknown status
Phase 1, Phase 2

Publications & Presentations

PubMed

Intraocular use of methotrexate (MTX) for the treatment of proliferative vitreoretinopathy (PVR) in congenital aniridia (CI) and a possible link to aniridia fibrosis s...
Naveen R Ambati, Christopher D Riemann
American Journal of Ophthalmology Case Reports. 2024-12-01
Pilot Safety Study of a Microfabricated Device for Anterior Stromal Puncture to Treat Corneal Epithelial Disease in the Optical Axis.
Edward Chaum, Dooho Brian Kim, Steven Kane, Forrest B Swann, Aaron Waite
Cornea. 2024-08-01
1 citations
Long-Term Control of Retinal Thickness Variability and Vision Following the 0.19 mg Fluocinolone Acetonide Implant.
Veeral S Sheth, Michael Singer, Mathew MacCumber, Antonio Cutino, Jonathan Kasper
Journal of Vitreoretinal Diseases. 2023-10-03

Press Mentions

Ergonomics: Care for Yourself to Improve Patient CareAugust 31st, 2022
Paladin Phase 4 Study Confirms Safety of Durable ILUVIEN® Treatment and Reduces Burden of Care for DME PatientsJuly 26th, 2022
Opregen® Data Update Will Be Featured at 54th Annual Retina Society Meeting in Podium Presentation by Christopher D. Riemann, M.D.September 13th, 2021
Join now to see all